Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the initiation of a Phase 2b clinical trial with the melanocortin agonist, bremelanotide. The BREAKOUT Study, entitled "A Phase 2b, Multicenter, Open-Label, Prospective Study of BREmelanotide in DiAbetic Kidney Disease to Assess the Efficacy in Reducing Urinary PrOtein and Maintaining Podocyte Density and FUncTion" initiated patient screening/enrollment in December 2022, and currently expects to initiate patient dosing in January 2023.
https://finance.yahoo.com/news/palatin-initiates-enrollment-phase-2-123000606.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.